Neuropeptide W-23 (human)
(Synonyms: NPW-23) 目录号 : GC16094
A neuropeptide ligand for GPR7 and GPR8
Cas No.:383415-79-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Neuropeptide W-23(human), the active form of Neuropeptide W, is an endogenous ligand for NPBW1 and NPBW2.
NPW-23 increases the ICa,L in transfected human embryonic kidney 293 cells and VSMCs via GPR7. NPW-23 increases the expression of pan phospho-PKC, intracellular diacylglycerol level, and the second messenger catalyzed by PLC[1].
NPW-23 increases pressure-induced vasotone of the rat mesenteric arteries. Importantly, the expression of NPW is decreased in the hypertensive rats[1]. NPW-23 (0.3 nmol, 1.0 nmol, and 3.0 nmol) induces significant increases in mean arterial pressure (MAP) in conscious, freely moving male rats. Rats that receive either 1.0 or 3.0 nmol NPW-23 demonstrate a significant increase in total activity, ambulatory activity, and duration of stereotypy. NPW-23 fails to elevate MAP in rats pretreated with phentolamine. NPW-23-induced increases in total activity, ambulatory activity, and duration of stereotypy are reduced significantly by pretreatment with the orexin type 1 receptor (OX1R) antagonist, SB-408124[2].
References:
[1]. Ji L, et al. Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7. J Hypertens. 2015 Dec;33(12):2431-42.
[2]. Pate AT, et al. Neuropeptide W increases mean arterial pressure as a result of behavioral arousal. Am J Physiol Regul Integr Comp Physiol. 2013 Oct 1;305(7):R804-10.
|
Animal experiment: |
Cardiovascular experiments are conducted the day after carotid implantation. On the day of the experiment, animals are habituated to a quiet room for at least 2 h. The carotid cannula is flushed with heparinized saline (200 U/mL in 0.9% NaCl) and connected to a pressure transducer. Baseline MAP is recorded for at least 30 min at 1-min intervals. For all experiments, preinjection baseline is calculated as the average MAP for 10 min before intracerebroventricular injections of saline or NPW-23. To test the cardiovascular effects of centrally administered NPW-23, rats are treated intracerebroventricularly with vehicle or vehicle containing 0.3, 1.0, or 3.0 nmol NPW-23. MAP is recorded for at least 45 min at 1-min intervals. To determine the potential role of sympathetic activation in mediating NPW-induced MAP increase, rats are pretreated intra-arterially with the α-adrenergic antagonist phentolamine-HCl (10 mg/kg body wt in 0.9% NaCl) or saline 15 min before central injection of saline or saline containing 1.0 nmol NPW-23. In a final experiment, the OX1R antagonist, SB-408124, or vehicle is injected intracerebroventricularly 15 s prior to 1.0 nmol NPW-23, and MAP is monitored for 45 min at 1-min intervals. |
|
References: [1]. Ji L, et al. Modulation of CaV1.2 calcium channel by neuropeptide W regulates vascular myogenic tone via G protein-coupled receptor 7. J Hypertens. 2015 Dec;33(12):2431-42. |
|
| Cas No. | 383415-79-0 | SDF | |
| 别名 | NPW-23 | ||
| 化学名 | (6S,7Z,9S,10Z,12S,13Z,15S,16Z,18S,19Z,22Z,24S,25Z,27S,28Z,30S,31Z,34Z,36S,37Z,39S,40Z,42S,43Z,46Z,48S)-12-((1H-imidazol-5-yl)methyl)-6-((Z)-(((S)-1-((2S,3Z,5S,6Z,8S,9Z,11S,12Z,14S,15Z,17S,18Z,20S)-11-((1H-imidazol-5-yl)methyl)-20-amino-14-(4-aminobutyl)-4 | ||
| Canonical SMILES | CC(C[C@@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/C/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@]1([H])CCCN1C([C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](/N=C(O)/[C@](N)([H])CC2=CNC3 | ||
| 分子式 | C119H183N35O28S | 分子量 | 2584.03 |
| 溶解度 | Soluble to 1 mg/ml in sterile water | 储存条件 | Desiccate at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.387 mL | 1.935 mL | 3.8699 mL |
| 5 mM | 0.0774 mL | 0.387 mL | 0.774 mL |
| 10 mM | 0.0387 mL | 0.1935 mL | 0.387 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: 95.08%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet